Beijing Neoletix Biological Technology

Neoletix is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation T-cell receptor engineered T-cell (TCR-T) therapies for solid tumors. The company focuses on targeting intracellular antigens and tumor-specific markers, such as Alpha-fetoprotein (AFP), to address unmet needs in liver cancer and other difficult-to-treat malignancies. Neoletix utilizes a proprietary technology platform to identify high-affinity TCRs and optimize cell manufacturing processes. Their lead candidate has entered clinical trials, demonstrating the company's transition from discovery to human proof-of-concept. By leveraging advanced gene editing and cell engineering, Neoletix aims to provide more effective and safer immunotherapy options for cancer patients.